Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Item

http://www.wikidata.org/entity/Q33574416

Q33574416

about

Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Chemotherapy in early breast cancer: when, how and which one?Breast Cancer 2012 - New Aspects The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials Modelling chemotherapy effects on granulopoiesis.Sentinel Lymph Node Biopsy in Early Breast Cancer.Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.Incidence of acute myeloid leukemia after breast cancer.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Trial watch: Chemotherapy with immunogenic cell death inducers Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Supportive therapy in medical therapy of head and neck tumors.Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).At cancer diagnosis: a 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Present status of adjuvant chemotherapy for elderly breast cancer patients.Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.Chemotherapy regimens in early breast cancer: major controversies and future outlook.Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.

P2860

Q26751249-ED7EE915-FD1A-4791-A7DE-50186AD37302 Q26751253-14B78F53-8EE9-4C7A-9BE1-482A465E16D1 Q26853619-E96D6E31-C774-4B21-9E21-6D30516C1826 Q30313214-9D8D6CD3-6CEE-45C7-BCA3-3AC4A6F3165B Q30317570-F1FE9D8A-6BF7-4884-B126-2CB00AC986D3 Q30318240-53AB0097-3A1F-4F12-B9B1-AC1422CB6EE7 Q30318610-FBEE7269-82B5-4447-9A0B-05320DBD4117 Q30588206-1DC1ED4D-4FB7-4473-9EC0-9870531E0969 Q33436678-FBC74007-376D-4D85-A405-08B901010C23 Q33659628-1DB3D85B-3019-40EA-AD3E-F722316BC8BE Q33827045-96F6C7F0-0491-4797-999D-2A4F56046674 Q34042627-6AF2F960-E724-4BAB-A0BC-206E04F1BB01 Q34042640-8C6250EF-EA2D-49EE-AD10-3234AB43B62C Q34209663-44F08433-62A0-4C99-90EC-6DF3C763E4B9 Q34352408-FD162164-AC98-47DB-A17D-74CB86A076D8 Q34996295-97472899-9360-4B6B-A5BD-93841B833300 Q35095599-66A60B0A-DE0E-4DCE-A0CD-1FB63A372152 Q35157554-B1CC04E2-A685-4DC7-BCF3-FEBC56D6A709 Q35168681-4D9640B0-4B3A-4AFD-8102-2530048BF5E0 Q35623087-7BC60443-0189-41FC-B3BB-A75C202D701E Q35640784-539D23A8-7E8B-431F-866C-0D6BE685272C Q35858979-26FAE811-09B9-4BD5-B8E2-2BDA24C66AB0 Q36038456-3CB4C21A-0E25-4C54-94FD-1517D13C98C7 Q36379148-03BA99E5-C585-4D66-8287-58C4E61DFC3F Q36529853-31FC605C-B87E-4DAB-B6AF-C81E1A574A95 Q37021210-75CFF362-7516-43D0-BF23-912B9FFA100B Q37132369-DEBB1501-E9C9-487E-AB43-7E72A2142DFD Q37174738-277CA8A7-CC62-4860-83C0-821B86FBAC8F Q37228051-529CD7D3-BBE1-4B3A-B4BF-EB11AE563996 Q37293242-50D843BA-A51E-456C-B175-329B6C390DA7 Q37309845-1BE601F7-D139-4EE5-A566-AD8D1E810840 Q37507392-32FE622D-629B-498E-8521-D13E1BD7B29C Q37657782-AF6FB83E-BE1E-4245-816D-072C9C1EA845 Q37677693-2B988775-D1BF-4548-9C66-B786D2855706 Q37722185-237ECE7E-4203-44BF-8612-6082E4854A7B Q38040419-BF2EAD0B-AA9F-4F1C-AC92-53EDFEF52293 Q38046516-97CEDEF2-2F05-4B6C-990F-CBA8F8E5F62B Q38056750-8F75985D-61D6-4B75-9F7E-6D6E710544B7 Q38081243-77015502-2442-46AB-86BC-7CF7A9FDD9D6 Q38115153-AD153029-F7AB-494B-8DB7-F88633B71C83

P2860

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Item

http://www.wikidata.org/entity/Q33574416

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu